Telesis Bio Moves Forward with Nasdaq Delisting
Telesis Bio Inc. (NASDAQ: TBIO), known for its RNA and DNA solutions, has decided to voluntarily remove its common stock from the Nasdaq Stock Market. The company says the move follows ongoing difficulties staying in line with Nasdaq’s listing standards. It’s a significant shift in how its shares will trade, but one the company frames as a practical next step.
Why the Company Is Taking This Step
Telesis has notified Nasdaq that it plans to delist its common stock and deregister under the Securities Exchange Act. The main issue: stockholders’ equity. Nasdaq rules require at least $10 million in stockholders’ equity. After receiving a 180-day extension to regain compliance, Telesis concluded it would not be able to meet that threshold within the allowed time.
Additional Compliance Pressures
In June, Nasdaq informed Telesis that its Market Value of Publicly Held Shares (MVPHS) had dropped below the required $5 million minimum. That notice added another layer of pressure, making the path back to full compliance even steeper. Taken together, these factors led the company to pursue delisting as a measured way to reduce listing-related burdens and refocus on its core work—potentially including private sales channels and other trading venues outside a national exchange.
What Trading Could Look Like Next
After the delisting becomes effective, Telesis Bio expects its shares to be quoted on an over-the-counter (OTC) market. Trading can continue there, often with fewer formal requirements than on a national exchange, which may give investors a degree of continuity. That said, the company cautions there are no assurances regarding the availability of market makers, the depth of trading, or the smoothness of ongoing transactions in the OTC market.
Focus Beyond the Ticker
Through the transition, Telesis says it remains committed to what it does best: enabling advanced synthetic biology. Its tools for DNA and mRNA synthesis support a wide range of research and medical applications. By concentrating on its technology and customers, the company aims to navigate near-term market challenges while continuing to support work that matters in the lab and, eventually, at the bedside.
About Telesis Bio
Telesis Bio has built a presence in synthetic biology by developing methods and systems that speed up design and build cycles. The company developed the Gibson Assembly method—widely used for DNA synthesis—alongside the first commercial automated benchtop systems for both DNA and mRNA synthesis. These capabilities are designed to deliver rapid, precise constructs, helping reduce development timelines for critical biomedical applications.
Ongoing Commitment to Innovation
The company continues to support researchers worldwide in areas such as precision medicine, vaccine development, and gene therapy, where time and accuracy are essential. While operating on the OTC markets can come with its own hurdles, Telesis aims to keep its foundational work in biotechnology moving forward, supporting customers who rely on consistent, high-quality synthesis tools.
Frequently Asked Questions
Why is Telesis Bio choosing to delist from Nasdaq?
The company determined it could not meet Nasdaq’s listing standards, including the minimum $10 million stockholders’ equity requirement, even after a 180-day extension. It also received notice in June that its Market Value of Publicly Held Shares had fallen below the $5 million minimum.
What happens to the stock after the delisting?
Telesis Bio expects its shares to be quoted on an over-the-counter (OTC) market. That would allow trading to continue outside a national exchange, though the company can’t guarantee market-making activity or trading liquidity.
Does this change how the business operates day to day?
The trading venue is changing, but the company says its focus stays the same: delivering tools for DNA and mRNA synthesis and supporting research across medical and scientific fields.
Will Telesis Bio keep investors informed after delisting?
Yes. The company says it will continue to meet its reporting obligations and provide updates on its activities and developments so investors can follow its progress.
What products and capabilities does Telesis Bio provide?
Telesis Bio offers systems and methods for rapid, precise DNA and mRNA synthesis—including technology associated with the Gibson Assembly method and automated benchtop synthesis platforms—used in precision medicine, vaccine research, gene therapy, and related areas.
